Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML

Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups

Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma

EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs

Clinical utility of molecular tumour profiling in breast cancer

Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM

Latest in combination therapy for NDMM patients

Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma.

Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients

Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies